Recombinant oncolytic viruses for treatment of metastatic cancers
US12378289B2 · kind B2 · utility
0Cited by
2References
5Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jun 22, 2018 |
| Grant date | Aug 5, 2025 |
| Priority date | — |
| Expiry date | Mar 8, 2040 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2760/20232
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Disclosed are recombinant oncolytic viruses that express one or more reovirus fusion-associated small transmembrane FAST) proteins and uses thereof. The oncolytic activity of the recombinant oncolytic viruses expressing FAST proteins can be used to treat primary and metastatic cancers, especially from breast and colon cancers.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.